pegamotecan
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2003 (NCT00079950)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@]1(OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@]2(CC)C(=O)OCc3c2cc2n(c3=O)Cc3cc4ccccc4nc3-2)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1- Mol. weight
- 980.98 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989476 ↗
- ChEMBLCHEMBL2104977 ↗
Also known as
- ez-246
- ez-246
- pegamotecan
- pegamotecan
- pegamotecan
- pegamotecan
- pegamotecan
- peg-beta-camptothecin
- peg-beta-cpt
- peg-camptothecin
- polyethylene glycol-conjugated camptothecin-20-o-glycinate
- prothecan
- prothecan
- prothecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00080002 | Phase 2 | Dec 1, 2003 | Enzon |
| NCT00079950 | Phase 2 | Aug 1, 2003 | Enzon |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enzon | For profit | 2 | 2 | 1 | 2003 |
1 organizations
Page 1 / 1